Madhavi Latha Somaraju

Scientist II at Mnemo Therapeutics

Dr. Madhavi Latha Somaraju (Chalasani) has a wealth of experience in the scientific field. Dr. Madhavi Latha began their career in 2001 as a Management Trainee at Shasun, where they were responsible for cloning and amplifying recombinant erythropoietin producing bacteriophage. In 2003, they began their Ph.D at L.V. Prasad Eye Institute, where they studied the function of the glaucoma-associated protein optineurin and its mutants. Dr. Madhavi Latha was also a Project Assistant at the same institute. In 2008, they moved to Centre for Cellular and Molecular Biology as a Research Associate. Here, they independently lead a project and demonstrated retinal cell-specific disease pathogenic mechanism of glaucoma causing E50K mutant of optineurin. In 2010, they were a Postdoctoral Fellow at L.V. Prasad Eye Institute and a Project Investigator at Centre for Cellular and Molecular Biology. From 2015 to 2018, Dr. Somaraju was a Postdoctoral Research Fellow at Nanyang Technological University, Singapore, where they discovered a novel molecular mechanism by which CG-NAP, an adaptor protein, mediates T-lymphocyte migration. Currently, they are a Scientist II at Mnemo Therapeutics, where they are focused on understanding the role of CCR2+ cells in regulating vascular integrity and skin integrity in bleomycin-induced skin fibrosis model.

Dr. Madhavi Latha Somaraju (Chalasani) obtained their Doctor of Philosophy (Ph.D.) in Studies on the function of the glaucoma-associated protein optineurin and its mutants from the L.V.Prasad Eye Institute, Centre for Cellular and Molecular Biology/ University of Hyderabad between 2003 and 2008. Dr. Madhavi Latha then received their M.Sc in Bio-technology from Banasthali Vidyapith between 1999 and 2001. Finally, they obtained their B.Sc in Biotechnology from T.S.R and T.B.K. College between 1996 and 1999.

Location

New York, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Mnemo Therapeutics

1 followers

Mnemo Therapeutics is a biotechnology company focused on developing powerful cell therapies that create accessible cures for solid tumors and blood cancers. Its EnfiniT platform, a groundbreaking drug discovery engine, leverages a new class of antigens with greater tumor specificity and a suite of technologies to significantly improve T cell memory, persistence, and sensitivity. The result is dramatic improvement in the body’s immune response to overcome disease. Mnemo is built by a transatlantic team of scientists and biotech leaders united in their mission to create the most powerful immune therapies to deliver accessible cures for all patients in need.


Industries

Headquarters

Paris, France

Employees

51-200

Links